20 November, 2018
Single-use technology, designed for the manufacturing of biopharmaceutical products, has made major inroads over the last 30 years. First introduced in the late 1970s in the form of disposable capsules and a ...
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02487979)
This phase II trial studies how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Antibody drug conjugates, such as glembatumumab vedotin (also known as CDX-011 or CR011-vcMMAE), provide treatment with injections of therapeutic substances linked with specific antibodies in order to directly destroy tumor cells or to stimulate the immune system to destroy those cells.
This trial is sponsored by the National Cancer Institute (NCI). 
Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
20 November, 2018
05 October, 2018
When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000, only a handful of patent applications claiming ADCs had been published. As research cont...